Treating multiple sclerosis with natalizumab

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

(2011) Theo Rispens et al.   ANALYTICAL BIOCHEMISTRY

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism

(2011) Jaime Ramos-Cejudo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society

(2011) A. Ghezzi et al.   NEUROLOGICAL SCIENCES

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

(2011) P. Vermersch et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Primary central nervous system lymphoma in a patient treated with Natalizumab

(2010) Remy Phan-Ba et al.   ANNALS OF NEUROLOGY

Evolution of Nevi During Treatment With Natalizumab

(2010) Emeline Castela et al.   ARCHIVES OF DERMATOLOGY

Natalizumab and Progressive Multifocal Leukoencephalopathy

(2010) Clemens Warnke et al.   ARCHIVES OF NEUROLOGY

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

(2010) Augusto Miravalle et al.   ARCHIVES OF NEUROLOGY

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

(2010) G. C. Ebers et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

(2010) Chen S Tan et al.   LANCET NEUROLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

(2010) RA Bermel et al.   Multiple Sclerosis Journal

Safety and efficacy of natalizumab in children with multiple sclerosis

(2010) A. Ghezzi et al.   NEUROLOGY

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab in pediatric multiple sclerosis patients

(2010) E. Ann Yeh et al.   Therapeutic Advances in Neurological Disorders

Primary central nervous system lymphoma in a patient treated with natalizumab

(2009) Andreas Schweikert et al.   ANNALS OF NEUROLOGY

Natalizumab and central nervous system lymphoma: No clear association

(2009) Carmen Bozic et al.   ANNALS OF NEUROLOGY

Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro

(2009) M. Brickelmaier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

α4-Integrin antagonism with natalizumab

(2009) Olaf Stüve et al.   JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

(2009) J. Mellergård et al.   Multiple Sclerosis Journal

Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

(2009) Roberto Bergamaschi et al.   Multiple Sclerosis Journal

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

(2009) Aran F Labrijn et al.   NATURE BIOTECHNOLOGY

Safety profile of Tysabri: international risk management plan

(2009) P. Iaffaldano et al.   NEUROLOGICAL SCIENCES

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells

(2009) P. Kivisakk et al.   NEUROLOGY

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study

(2009) A. D. Goodman et al.   NEUROLOGY

Review: Natalizumab in the treatment of multiple sclerosis

(2009) Özgür Yaldizli et al.   Therapeutic Advances in Neurological Disorders

Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy

(2008) Kerstin Hellwig et al.   ARCHIVES OF NEUROLOGY

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

(2008) F. Zohren et al.   BLOOD

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients

(2008) Raija L.P. Lindberg et al.   JOURNAL OF NEUROIMMUNOLOGY

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY